Pergamum AB

Pergamum is a biopharmaceutical company that specializes in therapeutic peptides with a particular focus on topical application in dermatology and wound healing. The development pipeline at present includes three programs in clinical development, to treat skin infections (atopic dermatitis), as well as to prevent formation of post-surgical adhesions following flexor tendon repair surgery and, as an extension indication, following orthopedic surgery. Another program is in preclinical development, to promote healing of hard-to-heal wounds. Pergamum estimates its products to have a combined peak sales potential of greater than € 1 billion.

Pergamum recently merged and integrated three innovative biotech start-ups (DermaGen, PharmaSurgics and Lipopeptide) into one operational company to capture on synergies. Pergamum has built a business model, which combines leading-edge program management and business development. This approach will ultimately increase the success rate in Pergamum's drug development initiatives and minimize time-to-market. In addition, this model enables Pergamum to pursue multiple exit- and partnering opportunities, and enhance return on venture-financed biotech investments.